Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.
Triple Negative Breast Cancer (TNBC)
DRUG: Tenalisib
Clinical Benefit Rate (CBR), It is defined as the percentage of patients achieving complete response (CR), partial response (PR), or stable disease (SD) for 16 weeks or longer., 1 year|Duration of Clinical Benefit (DoCB), It is defined as the time from the first dose to disease progression or death on study from any cause, whichever occurs first in patients who achieve CR, PR or SD for 16 weeks or longer., 1 year|Overall Response Rate (ORR), Overall Response is defined as sum of CR and PR., 1 year|Progression Free Survival (PFS), It is defined as the time from the first dose to disease progression or death on study from any cause, whichever occurs first., 1 year
Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0, Number of adverse events reported by the patients, 1 year|Trough plasma concentrations of tenalisib/metabolite, plasma concentrations of drug, 1 year|Correlation of efficacy to baseline mutational status, Baseline mutational status and its correlation with efficacy, 1 year
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.